Taltz close to psoriatic arthritis approval in Europe

[Fred]

Following on from Taltz getting FDA approval for psoriatic arthritis, the Committee for Medicinal Products for Human Use (CHMP) has recommended it for use in Europe too.

Quote:

---

On 14 December 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Taltz.

Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.”

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

Source: ema.europa.eu

Taltz gets FDA approval for psoriatic arthritis

Taltz (ixekizumab)